DK3407909T5 - Cancerbehandling - Google Patents

Cancerbehandling Download PDF

Info

Publication number
DK3407909T5
DK3407909T5 DK17743494.1T DK17743494T DK3407909T5 DK 3407909 T5 DK3407909 T5 DK 3407909T5 DK 17743494 T DK17743494 T DK 17743494T DK 3407909 T5 DK3407909 T5 DK 3407909T5
Authority
DK
Denmark
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Application number
DK17743494.1T
Other languages
English (en)
Other versions
DK3407909T3 (da
Inventor
Macarena Peran
Julian Kenyon
Juan Antonio Marchal Corrales
Maria Angel Garcia Chaves
Original Assignee
Propanc Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Propanc Pty Ltd filed Critical Propanc Pty Ltd
Publication of DK3407909T3 publication Critical patent/DK3407909T3/da
Application granted granted Critical
Publication of DK3407909T5 publication Critical patent/DK3407909T5/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4826Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21001Chymotrypsin (3.4.21.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21004Trypsin (3.4.21.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK17743494.1T 2016-01-29 2017-01-27 Cancerbehandling DK3407909T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201630112 2016-01-29
ES201631662 2016-12-22
PCT/AU2017/050065 WO2017127892A1 (en) 2016-01-29 2017-01-27 Cancer treatment

Publications (2)

Publication Number Publication Date
DK3407909T3 DK3407909T3 (da) 2023-11-13
DK3407909T5 true DK3407909T5 (da) 2024-09-23

Family

ID=59396793

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17743494.1T DK3407909T5 (da) 2016-01-29 2017-01-27 Cancerbehandling

Country Status (14)

Country Link
US (2) US11376313B2 (da)
EP (1) EP3407909B1 (da)
JP (1) JP7058604B2 (da)
CN (1) CN108697771A (da)
AU (1) AU2017212151B2 (da)
CA (1) CA3012398A1 (da)
DK (1) DK3407909T5 (da)
ES (1) ES2965358T3 (da)
HK (1) HK1251794A1 (da)
IL (1) IL260814B2 (da)
MY (1) MY198500A (da)
NZ (1) NZ744845A (da)
SG (1) SG11201806318UA (da)
WO (1) WO2017127892A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108697771A (zh) 2016-01-29 2018-10-23 普罗潘克股份有限公司 癌症治疗
US20190134166A1 (en) 2016-04-12 2019-05-09 Propanc Pty Ltd Composition of proenzymes for cancer treatment
CN114848665B (zh) * 2022-06-22 2023-09-12 中南大学湘雅三医院 CD71-CD44-GEMs在制备治疗膀胱癌药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514388A (en) 1983-03-22 1985-04-30 Psaledakis Nicholas G Proteolytic enzymes in the zymogen form to treat sarcoma cells
US4978332A (en) 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
CZ283972B6 (cs) * 1995-05-17 1998-07-15 František Mudr. Trnka Farmaceutický prostředek s modulačním účinkem na zhoubné nádory a jeho použití
RU2149021C1 (ru) 1998-05-07 2000-05-20 Научный центр акушерства, гинекологии и перинатологии РАМН Способ фармакологического лечения аутоиммунного мужского бесплодия
US6670330B1 (en) 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
AU2002226650A1 (en) 2001-01-18 2002-07-30 Arnold Hoffman Redox therapy for tumors
JP2004182674A (ja) 2002-12-05 2004-07-02 Kureha Chem Ind Co Ltd バニリル脂肪酸アミドを含む抗腫瘍医薬組成物
WO2004062604A2 (en) 2003-01-10 2004-07-29 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
WO2004103355A1 (en) 2003-05-13 2004-12-02 Health Research Inc. Method for augmenting the antitumor activity of anti-cancer agents
DE10321725A1 (de) 2003-05-14 2004-12-02 Mucos Pharma Gmbh & Co Enzymhaltige Zusammensetzungen, daraus hergestellte diätetische Lebensmittel und Arzneimittel und ihre Verwendung für medizinische Zwecke
US20060093684A1 (en) 2004-10-28 2006-05-04 Iwao Takeda Seleniferous composition for producing antioxidase in vivo
KR100740989B1 (ko) 2005-07-22 2007-07-19 넨시스(주) 구형 항염·항암효소 과립제 및 이의 제조방법
KR101058136B1 (ko) 2007-11-09 2011-08-24 신동헌 캡시에이트 또는 디하이드로캡시에이트의 신규한 용도
PT3095458T (pt) * 2009-10-22 2018-11-09 Propanc Pty Ltd Composição farmacêutica para tratar cancro compreendendo tripsinogénio e quimiotripsinogénio
CZ307195B6 (cs) * 2013-11-18 2018-03-14 František Trnka Farmaceutická kompozice obsahující směs proenzymů a enzymů
WO2016020572A1 (es) 2014-08-04 2016-02-11 Universidad De Granada MEDIO DE CULTIVO Y MÉTODO DE ENRIQUECIMIENTO Y MANTENIMIENTO DE CÉLULAS MADRE CANCERÍGENAS (CSCs) MEDIANTE EL USO DE DICHO MEDIO
CN108697771A (zh) 2016-01-29 2018-10-23 普罗潘克股份有限公司 癌症治疗
US20190134166A1 (en) 2016-04-12 2019-05-09 Propanc Pty Ltd Composition of proenzymes for cancer treatment

Also Published As

Publication number Publication date
MY198500A (en) 2023-09-01
IL260814B (en) 2022-12-01
US20190038725A1 (en) 2019-02-07
DK3407909T3 (da) 2023-11-13
CA3012398A1 (en) 2017-08-03
HK1251794A1 (zh) 2019-03-15
IL260814B2 (en) 2023-04-01
SG11201806318UA (en) 2018-08-30
WO2017127892A1 (en) 2017-08-03
AU2017212151B2 (en) 2020-07-16
US20230089740A1 (en) 2023-03-23
US11376313B2 (en) 2022-07-05
IL260814A (en) 2018-10-31
ES2965358T3 (es) 2024-04-15
EP3407909B1 (en) 2023-08-09
CN108697771A (zh) 2018-10-23
EP3407909A1 (en) 2018-12-05
AU2017212151A1 (en) 2018-08-16
EP3407909A4 (en) 2019-09-18
JP2019507129A (ja) 2019-03-14
JP7058604B2 (ja) 2022-04-22
NZ744845A (en) 2023-04-28

Similar Documents

Publication Publication Date Title
IL296080B1 (en) Method for treating cancer
IL269026A (en) Methods of treating tumor
IL255261A0 (en) Methods for treating cancer
IL269371A (en) Treatment methods
EP3463464A4 (en) ASSOCIATION TREATMENT
PL3283527T3 (pl) Leczenie skojarzone nowotworów
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
PL3197456T3 (pl) Leczenie nowotworów
HUE059694T2 (hu) Készítmény rák kezelésére
IL284875A (en) Lasofoxifene treatment of breast cancer
KR20180084772A (ko) 암 치료를 위한 조합 치료법
IL265697B1 (en) Treatment of prostate cancer
EP3546020A4 (en) CANCER TREATMENT APPARATUS
PL3458052T3 (pl) Leczenie skojarzone nowotworu
IL264443A (en) Methods of treating prostate cancer
EP3413927A4 (en) CANCER THERAPY
DK3576740T3 (da) Cancerbehandling
EP3593139C0 (en) CANCER BIOMARKERS
HUE040167T2 (hu) Rákkezelés
EP3576791A4 (en) CALRETICULIN-MEDIATION CANCER TREATMENT
IL308399A (en) Methods of treating cancer
IL281600A (en) Methods of treating cancer
EP3493821A4 (en) METHOD OF TREATING THE RESPIRATORY TRACT
IL264277A (en) Crebbp related cancer therapy
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도